DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
Defense Health Agency Contracting Activity - DHACA
Free. Verify your email, then we send one reminder only.
- Posted
- May 4, 2026
- Amount
- Program total $10.1M
- Closes
- Sep 30, 2026 (in 14 days)
Similar opportunities open now
- DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 14 days
- DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 14 days
- DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 14 days
- DoW Autism Idea Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 36 days
- DoW Autism Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 36 days
Classification and identifiers
- Solicitation number
- HT942526ALSRPTIA
- Assistance listing (CFDA)
- 12.420
Amount
Program total $10.1M
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation. Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.